Federal appeals court backs Lilly Zyprexa patent

12/26/2006 | NYTimes.com

The court affirmed a lower court ruling that Eli Lilly's schizophrenia drug patent is valid, rejecting efforts by the Ivax unit of Teva Pharmaceutical Industries and Dr. Reddy's Laboratories to overturn Lilly's 2011 patent expiration. The judges also said "Lilly did not fail to disclose information" to the patent office as the two rival drugmakers had argued.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY